Tokyo Tape
Sign in
← PeptiDream

Half-year report · Q2

4587.TEDINET S100WHGM
Period2025-01-01 → 2025-06-30
Filed2025-08-07
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 48
MetricValuePeriodScopeSource row
Revenue¥8.5bn2025-01-01 → 2025-06-30Cons.Revenue IFRS
Revenue¥46.7bn2024-01-01 → 2024-12-31Cons.Revenue IFRS (5-year summary)
Revenue¥36.1bn2024-01-01 → 2024-06-30Cons.Revenue IFRS
Operating income−¥2.6bn2025-01-01 → 2025-06-30Cons.Operating profit loss IFRS
Operating income¥24.6bn2024-01-01 → 2024-06-30Cons.Operating profit loss IFRS
Profit before tax−¥2.9bn2025-01-01 → 2025-06-30Cons.Profit loss before tax IFRS
Profit before tax¥20.9bn2024-01-01 → 2024-12-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥24.7bn2024-01-01 → 2024-06-30Cons.Profit loss before tax IFRS
Net income (owners)−¥2.1bn2025-01-01 → 2025-06-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥15.0bn2024-01-01 → 2024-12-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥17.9bn2024-01-01 → 2024-06-30Cons.Profit loss attributable to owners of parent IFRS
Net income−¥2.1bn2025-01-01 → 2025-06-30Cons.Profit loss IFRS
Net income¥15.0bn2024-01-01 → 2024-12-31Cons.Profit loss IFRS (5-year summary)
Net income¥17.9bn2024-01-01 → 2024-06-30Cons.Profit loss IFRS
Total assets¥78.5bnat 2025-06-30Cons.Assets IFRS
Total assets¥92.8bnat 2024-12-31Cons.Assets IFRS
Total assets¥95.9bnat 2024-06-30Cons.Total assets IFRS (5-year summary)
Total liabilities¥24.9bnat 2025-06-30Cons.Liabilities IFRS
Total liabilities¥36.0bnat 2024-12-31Cons.Liabilities IFRS
Net assets / equity¥53.7bnat 2025-06-30Cons.Equity IFRS
Net assets / equity¥56.8bnat 2024-12-31Cons.Equity IFRS
Net assets / equity¥58.8bnat 2024-06-30Cons.Equity IFRS
Net assets / equity¥40.3bnat 2023-12-31vCons.Equity IFRS
Equity (owners)¥53.7bnat 2025-06-30Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥56.8bnat 2024-12-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥58.8bnat 2024-06-30Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥33.3bnat 2025-06-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥48.1bnat 2024-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥25.5bnat 2024-06-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥19.5bnat 2023-12-31vCons.Cash and cash equivalents IFRS
Operating cash flow−¥11.0bn2025-01-01 → 2025-06-30Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥23.8bn2024-01-01 → 2024-12-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow−¥2.7bn2024-01-01 → 2024-06-30Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥1.3bn2025-01-01 → 2025-06-30Cons.Net cash provided by used in investing activities IFRS
Investing cash flow¥8.4bn2024-01-01 → 2024-12-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow¥10.0bn2024-01-01 → 2024-06-30Cons.Net cash provided by used in investing activities IFRS
Financing cash flow−¥2.5bn2025-01-01 → 2025-06-30Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥3.0bn2024-01-01 → 2024-12-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥1.5bn2024-01-01 → 2024-06-30Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥-16.42025-01-01 → 2025-06-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥115.852024-01-01 → 2024-12-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥138.32024-01-01 → 2024-06-30Cons.Basic earnings loss per share IFRS
EPS (diluted)¥-16.42025-01-01 → 2025-06-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥115.682024-01-01 → 2024-12-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥138.112024-01-01 → 2024-06-30Cons.Diluted earnings loss per share IFRS
Equity ratio68.3%at 2025-06-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio61.2%at 2024-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio61.3%at 2024-06-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 26
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2025-01-01 → 2025-06-30−¥453m
Reconciling Itemsreconcilingrevenue intersegment2025-01-01 → 2025-06-30−¥453m
jpcrp040300-q2r_E27486-000Drug Discovery And Development Businessreportable segmentrevenue2025-01-01 → 2025-06-30¥761m
jpcrp040300-q2r_E27486-000Drug Discovery And Development Businessreportable segmentrevenue external2025-01-01 → 2025-06-30¥761m
jpcrp040300-q2r_E27486-000Drug Discovery And Development Businessreportable segmentsegment profit2025-01-01 → 2025-06-30−¥3.0bn
jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue2025-01-01 → 2025-06-30¥8.2bn
jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue external2025-01-01 → 2025-06-30¥7.8bn
jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue intersegment2025-01-01 → 2025-06-30¥453m
jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segmentsegment profit2025-01-01 → 2025-06-30¥436m
—segment totalrevenue2025-01-01 → 2025-06-30¥9.0bn
—segment totalrevenue external2025-01-01 → 2025-06-30¥8.5bn
—segment totalrevenue intersegment2025-01-01 → 2025-06-30¥453m
—segment totalsegment profit2025-01-01 → 2025-06-30−¥2.6bn
Reconciling Itemsreconcilingrevenue2024-01-01 → 2024-06-30−¥178m
Reconciling Itemsreconcilingrevenue intersegment2024-01-01 → 2024-06-30−¥178m
jpcrp040300-q2r_E27486-000Drug Discovery And Development Businessreportable segmentrevenue2024-01-01 → 2024-06-30¥28.5bn
jpcrp040300-q2r_E27486-000Drug Discovery And Development Businessreportable segmentrevenue external2024-01-01 → 2024-06-30¥28.5bn
jpcrp040300-q2r_E27486-000Drug Discovery And Development Businessreportable segmentsegment profit2024-01-01 → 2024-06-30¥24.7bn
jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue2024-01-01 → 2024-06-30¥7.8bn
jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue external2024-01-01 → 2024-06-30¥7.7bn
jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue intersegment2024-01-01 → 2024-06-30¥178m
jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segmentsegment profit2024-01-01 → 2024-06-30−¥47m
—segment totalrevenue2024-01-01 → 2024-06-30¥36.3bn
—segment totalrevenue external2024-01-01 → 2024-06-30¥36.1bn
—segment totalrevenue intersegment2024-01-01 → 2024-06-30¥178m
—segment totalsegment profit2024-01-01 → 2024-06-30¥24.7bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 582
ItemContextValueUnit
Independent auditors report consolidated (text)FilingDateInstantText · Plus
Audit firm1 consolidatedFilingDateInstant
Original text (Japanese)有限責任 あずさ監査法人
Cpa1 audit firm1 consolidatedFilingDateInstant
Original text (Japanese)猪　俣　　雅　弘
Cpa2 audit firm1 consolidatedFilingDateInstant
Original text (Japanese)中　島　　悠　史
Number of submissionFilingDateInstant1
Revenue IFRS (5-year summary)Prior1YTDDuration36133625000JPY
Revenue IFRS (5-year summary)CurrentYTDDuration8543788000JPY
Revenue IFRS (5-year summary)Prior1YearDuration46676523000JPY
Profit loss before tax IFRS (5-year summary)Prior1YTDDuration24742228000JPY
Profit loss before tax IFRS (5-year summary)CurrentYTDDuration-2862513000JPY
Profit loss before tax IFRS (5-year summary)Prior1YearDuration20888805000JPY
Profit loss attributable to owners of parent IFRS (5-year summary)Prior1YTDDuration17925302000JPY
Profit loss attributable to owners of parent IFRS (5-year summary)CurrentYTDDuration-2122490000JPY
Profit loss attributable to owners of parent IFRS (5-year summary)Prior1YearDuration15014922000JPY
Profit loss IFRS (5-year summary)Prior1YTDDuration17925302000JPY
Profit loss IFRS (5-year summary)CurrentYTDDuration-2122490000JPY
Profit loss IFRS (5-year summary)Prior1YearDuration15014922000JPY
Comprehensive income attributable to owners of parent IFRS (5-year summary)Prior1YTDDuration18394750000JPY
Comprehensive income attributable to owners of parent IFRS (5-year summary)CurrentYTDDuration-2122490000JPY
Comprehensive income attributable to owners of parent IFRS (5-year summary)Prior1YearDuration16216367000JPY
Comprehensive income IFRS (5-year summary)Prior1YTDDuration18394750000JPY
Comprehensive income IFRS (5-year summary)CurrentYTDDuration-2122490000JPY
Comprehensive income IFRS (5-year summary)Prior1YearDuration16216367000JPY
Equity attributable to owners of parent IFRS (5-year summary)Prior1QuarterInstant58770634000JPY
Equity attributable to owners of parent IFRS (5-year summary)CurrentQuarterInstant53673692000JPY
Equity attributable to owners of parent IFRS (5-year summary)Prior1YearInstant56762298000JPY
Total assets IFRS (5-year summary)Prior1QuarterInstant95881241000JPY
Total assets IFRS (5-year summary)CurrentQuarterInstant78537623000JPY
Total assets IFRS (5-year summary)Prior1YearInstant92769826000JPY
Basic earnings loss per share IFRS (5-year summary)Prior1YTDDuration138.30
Basic earnings loss per share IFRS (5-year summary)CurrentYTDDuration-16.40
Basic earnings loss per share IFRS (5-year summary)Prior1YearDuration115.85
Diluted earnings loss per share IFRS (5-year summary)Prior1YTDDuration138.11
Diluted earnings loss per share IFRS (5-year summary)CurrentYTDDuration-16.40
Diluted earnings loss per share IFRS (5-year summary)Prior1YearDuration115.68
Ratio of owners equity to gross assets IFRS (5-year summary)Prior1QuarterInstant0.613
Ratio of owners equity to gross assets IFRS (5-year summary)CurrentQuarterInstant0.683
Ratio of owners equity to gross assets IFRS (5-year summary)Prior1YearInstant0.612
Cash flows from used in operating activities IFRS (5-year summary)Prior1YTDDuration-2659911000JPY
Cash flows from used in operating activities IFRS (5-year summary)CurrentYTDDuration-10952568000JPY
Cash flows from used in operating activities IFRS (5-year summary)Prior1YearDuration23844988000JPY
Cash flows from used in investing activities IFRS (5-year summary)Prior1YTDDuration9956370000JPY
Cash flows from used in investing activities IFRS (5-year summary)CurrentYTDDuration-1287521000JPY
Cash flows from used in investing activities IFRS (5-year summary)Prior1YearDuration8370789000JPY
Cash flows from used in financing activities IFRS (5-year summary)Prior1YTDDuration-1485160000JPY
Cash flows from used in financing activities IFRS (5-year summary)CurrentYTDDuration-2479216000JPY
Cash flows from used in financing activities IFRS (5-year summary)Prior1YearDuration-2994633000JPY
Cash and cash equivalents IFRS (5-year summary)Prior1QuarterInstant25477479000JPY
Cash and cash equivalents IFRS (5-year summary)CurrentQuarterInstant33328222000JPY
Cash and cash equivalents IFRS (5-year summary)Prior1YearInstant48117933000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2024-12-31pass rounding
balance sheet identityconsolidated 2025-06-30pass rounding
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2024-01-01/2024-06-30pass
statement vs summary · net income attributable to parentconsolidated 2025-01-01/2025-06-30pass
statement vs summary · operating cash flowconsolidated 2024-01-01/2024-06-30pass
statement vs summary · operating cash flowconsolidated 2025-01-01/2025-06-30pass
statement vs summary · revenueconsolidated 2024-01-01/2024-06-30pass
statement vs summary · revenueconsolidated 2025-01-01/2025-06-30pass
statement vs summary · total assetsconsolidated 2024-12-31pass
statement vs summary · total assetsconsolidated 2025-06-30pass